Clinical Trial

Substantia Nigra Iron in Parkinson's Disease

Study Description

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Prospective, single center study to determine whether the current R2* iron mapping method for measuring nigral iron changes in the brain can be significantly improved by using the Quantitative Susceptibility Mapping (QSM) based iron mapping techniques with the goal of validating QSM for potential use in later clinical trials. Subjects with a diagnosis of Parkinson's Disease, Rapid Eye Movement (REM) Sleep Behavior Disorder, and Normal Volunteers who meet the inclusion and exclusion criteria will be eligible for participation in this study.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - (11C)PE2I

Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

Additional Information

Official Study Title

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls

Clinical Trial ID

NCT03675282

ParticipAid ID

b68Wle